AstraZeneca has announced plans for a USD 150 million facility in the country’s Kaluga region. To be located at the Vorsino industrial park, the facility will undertake all aspects of production from formulation to packaging. The plan is for the plant to produce 16 million packs a year for the local drug market. GlaxoSmithKline (GSK) and generic drugmaker Teva Pharmaceutical industries join AstraZeneca to reveal investment in Russia, all of which follow the Russian government’s call for drugmakers to expand production capacity in the country or risk facing what Prime Minister Vladimir Putin decribed as “restrictions.” The facility, work on which is scheduled to begin in March, will produce drugs for cancer, cardiovascular disease, neurological disorders, respiratory conditions and infections and will employ a staff of 145 people when fully operational in the spring of 2013.
